Stay up to date on the latest oncology and nursing conferences.
Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy
Daniel J. Verina, DNP, RN, MSN, ACNP-BC, underscores how nurses can assess neurological toxicities in both the inpatient and outpatient setting.
Maximizing Potential of Immunotherapy Requires Appropriate irAE Management
Immunotherapy has changed the face of cancer treatment, but requires appropriate irAE management to reach full potential.
Mepitel Film Reduces Severe Radiation Dermatitis in Patients Undergoing Mastectomy
The rate of severe radiation dermatitis was reduced with the use of Mepital Film in patients with breast cancer undergoing mastectomy.
5-Year Findings Support Xevinapant Plus Chemotherapy in Locally Advanced Head and Neck Cancer
A presentation at the 2022 ESMO Congress found that xevinapant plus chemoradiotherapy decreased the risk of death by twice that of placebo for patients with unresectable, locally advanced head and neck squamous cell carcinoma.
Nurse Leaders Must Foster Change to Develop a Healthy Workplace Environment
Linda Laskowski-Jones, MS, APRN, ACNS-BC, CEN, NEA-BC, FAAN, discusses how oncology nurse leaders can help improve working environments for their staff.
States With Medicaid Expansion Experience Improved Cancer Care Delivery
At the 2022 ASCO Quality Care Symposium, researchers discussed how Medicaid expansion was tied to earlier diagnoses, more accessible palliative care, and decreased mortality rates for patients with cancer.
Tivozanib Outperforms Sorafenib in Extending Overall Survival in Advanced RCC
Tivozanib, an oral VEGF inhibitor, improved overall survival in patients with relapsed or refractory, advanced renal cell carcinoma.
Dose Reductions Help Patients with Breast Cancer Stay on Abemaciclib Longer
At the 2022 ASCO Quality Care Symposium, an adverse event analysis showed that abemaciclib has a manageable safety profile and that dose reductions may be a key aspect of appropriate symptom management.
Neratinib Yields Robust Responses in Patients with HER2-Mutated Cervical Cancer
Neratinib was associated with a clinical benefit rate of 45.5% among patients with metastatic or recurrent HER2-mutated cervical cancer.
Milagros Elia Underscores How Oncology Nursing and Climate Health Are Intertwined
In this episode of "The Vitals," Milagros Elia, MA, APRN, ANP-BC, highlights how oncology nurses play a role in ongoing conversations regarding the intersection of climate change and public health.
Rise of Oral Cancer Drugs Signal Deeper Financial Toxicity Issues for Patients
Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.
Promising Pathologic Complete Response Rate Observed With Neoadjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma
Neoadjuvant cemiplimab elicited promising pathologic complete responses in patients with cutaneous squamous cell carcinoma.
Climate Change and Evolving Threats to Public Health: The Oncology Nurse’s Role
Milagros Elia, MA, APRN, ANP-BC, discusses ways that nurses can advocate for their patients and help them manage health-related symptoms in the context of changing local environments.
Addition of Abemaciclib to Aromatase Inhibitor Therapy Prolongs Survival in HR+/HER2- Breast Cancer
For patients receiving an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer, the addition of abemaciclib doubled median progression-free survival vs placebo.
Phase 3 Findings Showcase PFS Benefit with Sotorasib for Patients With KRAS G12C+ NSCLC
Sotorasib doubled the progression-free survival rate in patients with KRAS G12C–mutated non–small cell lung cancer.
Nurse-Led Research Links Saturate Fatty Acids to Improved Immunotherapy Responses in NSCLC
Julie Malo, CCRP, a research nurse with the University of Montreal, discusses a nurse-directed initiative examining how the gut microbiome affects immune checkpoint blockade responses in patients with non–small cell lung cancer.
Tislelizumab Rivals Sorafenib in Improving OS in Unresectable Hepatocellular Carcinoma
Patients with hepatocellular carcinoma achieved a median overall survival of 15.9 months with tislelizumab and 14.1 months with sorafenib.
Lenvatinib Dose Escalation Is Associated With Favorable Outcomes in Patients with HCC
In a real-world analysis of patients with hepatocellular carcinoma, the median overall survival with lenvatinib was 9.7 months in the low-dose group and 7.6 months in the recommended-dose group.
Oncology Nurses Must Understand the Later Effects of HSCT To Provide Adequate Survivorship Care
In a presentation at the 2022 Oncology Nursing Society Bridge, Stephany L. Rodriguez, RN, MS, NP, discussed the later effects associated with hematopoietic stem cell transplant and how to manage them.
Daly Discusses Biomarkers and Emerging Targeted Therapies for Cancer Care
Kristin Daly, MSN, ANP-BC, AOCNP, discusses the clinical significance of tumor variants and how they are changing the direction of cancer care.
TIL Therapy Outperforms Ipilimumab in Extending Progression-Free Survival in Unresectable Melanoma
At a median follow-up of 33.0 months, the median progression-free survival with tumor-infiltrating lymphocyte therapy was 7.2 months vs 3.1 months with ipilimumab.
Real-World HRQOL Findings Support Nivolumab for Previously Treated mRCC
Results of retrospective analysis of previously treated patients with metastatic renal cell carcinoma who received nivolumab in the second- and third-line showed that health-related quality of life was maintained in the real-world setting
Pembrolizumab Plus Bevacizumab and Cyclophosphamide Shows Promising Efficacy, Tolerability in Recurrent Ovarian Cancer
Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Pembrolizumab Potentially Most Effective Before Surgery in High-Risk Melanoma
The rate of event-free survival associated with pembrolizumab was significantly higher among patients with high-risk melanoma about to undergo surgery than among those who received immunotherapy following surgery.
Trastuzumab Deruxtecan Continues to Elicit Encouraging Responses in Patients With Metastatic Gastric/GEJ Cancer
After 10 months of follow-up, the confirmed objective response rate among patients with metastatic gastric cancer or gastroesophageal junction adenocarcinoma who received trastuzumab deruxtecan was 41.8%.
Oncology Nurses: What Cannabinoid Is Your Patient Taking?
Karen Hande, PhD(c), DNP, ANP-BC, CNE, FAANP, ANEF, explains the difference between some of the popular cannabinoid products that patients with cancer may be taking.
Real-World Data Show TRAEs Associated With Improved Survival With Atezolizumab plus Bevacizumab in HCC
A multicentre, retrospective study showed that treatment-related adverse effects associated with atezolizumab plus bevacizumab were prognostic of improvements in survival outcomes in patients with hepatocellular carcinoma.
Dose-Optimized Regorafenib Provides Comparable, Safe Option for mCRC
Patients with relapsed or refractory metastatic colorectal cancer who received dose-optimized regorafenib achieved superior survival outcomes than those who received best supportive care, fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil.
Neoadjuvant Nivolumab/Ipilimumab Yields 95% Major Pathological Response Rate in dMMR Colon Cancer
Neoadjuvant immunotherapy starkly outperformed neoadjuvant chemotherapy in eliciting major pathological responses among patients with mismatch repair–deficient colon cancer, according to investigators.
5-Year Follow-Up Shows Neoadjuvant T-VEC Benefit in Patients with Resectable Melanoma
The relapse-free survival rate was 22.3% among patients with resectable stage IIIB to IV M1a melanoma who received neoadjuvant talimogene laherparepvec versus 15.2% among those who received surgery alone.
Endocrine Therapy Plus Ovarian Suppression Remains An Effective Treatment Strategy in HR+, HER2-, Early Breast Cancer
Investigators Present Real-World Experiences With T-DXd Following HER2 Status Changes
Maintenance Pembrolizumab/Olaparib Falls Short in Locally Advanced, Metastatic TNBC
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
2 Clarke Drive Cranbury, NJ 08512